COVID-19 Impact on the global Infertility Treatment Market
The coronavirus pandemic is currently presenting various challenges to clinical healthcare providers and patients across the globe. Logistical issues, managing patients with the disease, prioritizing patients with comorbidities and pre-existing conditions, and protecting public & hospital frontline workers from exposure to the COVID-19 infection are the major challenges faced by healthcare systems across the globe.
One in six reproductive-aged couples experiences infertility, and many turn to treatments such as intrauterine insemination (IUI) and in vitro fertilization (IVF), which require in-person appointments to complete. In India, 30 lakh people seek infertility treatment every year, but only 5 lakh people undergo IVF/intrauterine insemination (IUI) procedures.
During the COVID-19 pandemic, a 90% drop was observed in the number of people undergoing IVF cycles. The spread of COVID-19 has not only impacted fertility clinics owing to the cancellation of IVF treatments but has also impacted fertility decisions among couples who were opting for IVF treatment before the pandemic.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43497112
Growth in the infertility treatment market is primarily driven by factors such as the declining fertility rate, rising number of fertility clinics worldwide, technological advancements, and increasing public-private investments, funds, and grants. However, the high procedural costs of assisted reproductive technology procedures in developed markets and unsupportive government regulations for certain infertility treatment options are expected to limit market growth to a certain extent.
The fertility rate worldwide is declining steadily owing to various factors, such as the growing trend of late marriages and increasing age-related infertility. Global fertility rates are projected to decline to 2.4 children per woman by 2030 and 2.2 children per woman by 2050. This declining fertility rate has led to a significant increase in the demand for infertility treatment products that determine the fertility window in males and females.
Along with fertility surgeries, thousands of cycles of ART procedures such as in vitro fertilization (IVF) are performed every year globally. The cost of IVF treatment varies from country to country due to the lack of reimbursement policies. A lack of insurance coverage and the poor reimbursement scenario in some parts of the world are limiting the growth of this market.
Additionally, the medical tourism industry in emerging countries is thriving owing to a number of factors. In Asia, healthcare facilities are of high quality, treatment procedures are affordable, and many of the doctors and surgeons are trained and educated in the top institutes in the US and Europe. Emerging countries such as India, China, Singapore, Thailand, Brazil, and Malaysia present significant opportunities for the growth of the infertility treatment market.
Request To Get Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=43497112
To leverage the significant growth opportunities in emerging countries, players are increasingly focusing on undertaking strategic developments agreements/partnerships with regional/domestic players, geographical expansions, and acquisitions.to increase their presence in these markets and tap a large number of customers. In addition, government \initiatives to increase the accessibility of infertility treatments, and the growing number of fertility centers are also fuelling the growth of infertility treatment procedures in emerging countries.
Assisted reproductive technology (ART) involves procedures that require the handling of the human egg and embryos. Since the inception of ART procedures, there have been various ethical, legal, and societal controversies regarding the safe administration of gonadotropins, transparency of pregnancy data from clinics, and addressing economic barriers to ART access. Issues related to embryos and what to do with unused embryos are one of the major concerns related to the ART procedure.
In order to monitor activities related to ART procedures, strict regulations have been formulated by authorities in various countries across the globe. Authorities such as the International Federation of Fertility Societies (IFFS), European Society of Human Reproduction and Embryology (ESHRE), Indian Council of Medical Research (ICMR), Ethics Committee of American Society for Reproductive Medicine (ASRM), and Human Fertilization and Embryology Authority (HFEA) have implemented stringent regulations for infertility treatment.
The equipment to capture the largest share in infertility treatment market, by products during the forecast period.
The equipment segment is expected to witness the highest growth rate during the forecast period. The high growth in this owes to the technological advancements and presence of well-established players with strong product portfolio. Along with this growing focus of players towards base expansion through adopting various strategies such as new equipment launch, showcase across the globe is likely to contribute towards the growth of the segment.
The assisted reproductive technology (ART) to capture the largest market share of infertility treatment market, by procedure in 2021.”
The assisted reproductive technology segment captured the largest share of the infertility treatment market procedures during the forecast period. The growing awareness of the presence of ART, rise in success rate of this procedure and growing worldwide acceptance of ART is likely to boost the growth of the segment.
Key Market Players
The prominent players operating in the global infertility treatment market include The Cooper Companies Inc. (US), Cook Group (US), Vitrolife (Sweden), Thermo Fisher Scientific, Inc. (US), Esco Micro Pte. Ltd. (Singapore), Genea Biomedx (Australia), IVFtech ApS (Denmark), FUJIFILM Irvine Scientific (US), The Baker Company, Inc. (US), Kitazato Corporation (Japan), Rocket Medical plc (UK), IHMedical A/S (Denmark), Hamilton Thorne Ltd. (US), ZEISS Group (Germany), MedGyn Products, Inc. (US).
